Low dose naltrexone (LDN) has been implicated to help with cancer, HIV/AIDS, autoimmune diseases, and much more. Now it has been shown to have a potent antitumor effect on human ovarian cancer in both tissue culture and in animal xenografts. Naltrexone (NTX) is a general opioid receptor antagonist that results in compensatory elevation in endogenous opioids and opioid receptors. It has a powerful inhibition of cell proliferation. Studies showed that LDN could also increase the effects of chemotherapy for ovarian cancer.